Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐ cell lymphoma: Insights from real‐life clinical practice
Cancer Reports · 2024
DOI: 10.1002/cnr2.1983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Jasmine Mohamad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva and Swiss Cancer Center Leman, Geneva, Switzerland. Hauptthemen laut MEDLINE: Tumor Lysis Syndrome, Rituximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tumor lysis syndrome (TLS) is a potentially life‐threatening condition resulting from the rapid destruction of malignant cells, leading to electrolyte imbalances and severe complications, such as acute kidney injury, arrhythmias, and seizures. TLS can be managed through hyperhydration, urate‐lowering treatments, and a steroid prophase strategy.
Aims
This study aims to explore the impact of fractionated rituximab, an anti‐CD20 antibody, on the occurrence and severity of TLS during the initial cycle in patients with aggressive B‐cell non‐Hodgkin lymphoma (B‐NHL).
Methods
Data was retrospectively collected from 94 of 186 patients.
Results
Among the 94 patients included in the analysis, the median age was 70. Histologies were diffuse large B‐cell lymphoma (75%), Burkitt lymphoma (13%) and high‐grade B‐cell lymphoma (8%). The majority were at an advanced stage (93%) with a high IPI score (75%). Most patients received anthracycline‐containing regimens (72%) and prophylactic allopurinol (83%) and/or rasburicase (26%). Steroid prophase was administered to 82% of patients. The study identified one clinical TLS case and six laboratory TLS cases. Significant TLS factors included BL histology, elevated baseline LDH (⟩500 U/l), and rasburicase usage. Infusion reactions were rare (3%). Median progression‐free survival was 2.6 years, and 2‐year overall survival was 33%, irrespective of TLS occurrence.
Conclusion
In this real‐life study, clinical TLS occurrence was low (1%). TLS appeared more frequent in BL but did not impact overall survival. Fractionated initial rituximab dosing in addition to preventive strategies is a feasible approach in preventing clinical TLS, warranting further prospective investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Research Centre in Onco-Hematology, Faculty of Medicine, University of Geneva and Swiss Cancer Center Leman, Geneva, Switzerland.
- Division of Clinical Pathology, Diagnostic Department, Geneva University Hospital, Geneva, Switzerland.
- Department of Patho-Immunology, Geneva University Medical Centre, Geneva, Switzerland.
- Department of Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
- Department of Hematology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
- Department Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands.
ORCID-Profile: Thomas A McKee, Noémie Lang
Zitieren
APA
Mohamad, J., Bouroumeau, A., McKee, T. A., Mach, N., Samii, K., Chamuleau, M., Stenner, F., Tamburini, J., & Lang, N. (2024). Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐ cell lymphoma: Insights from real‐life clinical practice. Cancer Reports. https://doi.org/10.1002/cnr2.1983
Vancouver
Mohamad J, Bouroumeau A, McKee TA, Mach N, Samii K, Chamuleau M, et al. Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐ cell lymphoma: Insights from real‐life clinical practice. Cancer Reports. 2024. doi:10.1002/cnr2.1983
BibTeX
@article{Mohamad2024,
author = {Mohamad, Jasmine and Bouroumeau, Antonin and McKee, Thomas A and Mach, Nicolas and Samii, Kaveh and Chamuleau, Martine and Stenner, Frank and Tamburini, Jerome and Lang, Noémie},
title = {Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B‐ cell lymphoma: Insights from real‐life clinical practice},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.1983}
}
EUVIMED